论文部分内容阅读
目的研究胃癌患者SLCO1B3基因多态性与多西他赛化疗引起的骨髓抑制的相关性。方法共纳入61例接受多西他赛化疗的胃癌患者,采用飞行时间质谱法检测SLCO1B3基因多态性,研究不同SLCO1B3基因分型与骨髓抑制风险发生的相关性。结果 SLCO1B3 AA型42例(68.9%),AG型16例(26.2%),GG型有3例(4.9%)。Logistic回归分析发现,不同SLCO1B3基因型与骨髓抑制发生风险之间无统计学差异[共显性遗传模型:杂合子(AG)vs.野生型(AA),优势比(OR)=0.341,95%置信区间(95%CI):0.101-1.156;纯合子(GG)vs.(AA),OR=0.375,95%CI:0.031-4.465;显性遗传模型:(AG+GG)vs.AA,OR=0.346,95%CI=0.110-1.087;隐性遗传模型:GG vs.(AG+AA),OR=0.500,95%CI=0.043-5.823]。进一步对患者各临床特征与骨髓抑制发生风险之间进行统计学分析,结果发现二者之间也不存在相关性。结论 SLCO1B3基因多态性不能作为预测本组人群多西他赛化疗相关骨髓抑制的基因预测指标。
Objective To investigate the association between SLCO1B3 gene polymorphism and myelosuppression induced by docetaxel chemotherapy in gastric cancer. Methods A total of 61 patients with gastric cancer receiving docetaxel chemotherapy were enrolled. The SLCO1B3 gene polymorphisms were detected by time of flight mass spectrometry to study the association between different SLCO1B3 genotypes and the risk of myelosuppression. Results SLCO1B3 type AA 42 cases (68.9%), AG type 16 cases (26.2%), GG type 3 cases (4.9%). Logistic regression analysis showed that there was no significant difference between the SLCO1B3 genotypes and the risk of myelosuppression [co-dominant genetic model: heterozygote (AG) vs wild type (AA), OR = 0.341, 95% Confidence interval (95% CI): 0.101-1.156; Homozygous (GG) vs. (AA) OR = 0.375, 95% CI: 0.031-4.465; Dominant genetic model: (AG + GG) vs.AA, OR = 0.346, 95% CI = 0.110-1.087; recessive genetic model: GG vs. (AG + AA), OR = 0.500, 95% CI = 0.043-5.823]. Further analysis of the clinical characteristics of patients and the risk of myelosuppression between the statistical analysis, the results found no correlation between the two. Conclusion SLCO1B3 gene polymorphism can not be used as a predictor of myelosuppression in predicting myelosuppression in this population.